obesity

News

Martin Holst Lange, Novo Nordisk's head of development

Novo charts course ahead for CagriSema after lacklustre data

After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track.

News

Novo rises on Wegovy sales leap, but warns of a slowdown

Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.

News

Two more biotechs, Metsera and Maze, cross IPO finish line

Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.

News

Veru shares plunge despite positive data in obesity trial

Veru's obesity candidate achieved the objective of preserving muscle in people taking weight-loss drug Wegovy, but its share price still fell sharply.

Patients

social media illustration overlay on smart phone use

Social media advocacy: Healthcare professionals and the Trea...

Social media is a hub of opinion, argument, and advocacy that traverses a virtually endless spectrum.

News

Novo Nordisk leaps on new obesity drug data

Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.

Novo charts course ahead for CagriSema after lacklustre data

Novo rises on Wegovy sales leap, but warns of a slowdown

Two more biotechs, Metsera and Maze, cross IPO finish line

Veru shares plunge despite positive data in obesity trial

Social media advocacy: Healthcare professionals and the Trea...

Novo Nordisk leaps on new obesity drug data

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

obesity

Editor's Picks